Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.2 Million CAD | 49.13% |
| 2022 | 1.26 Million CAD | -28.26% |
| 2021 | 1.76 Million CAD | 103.2% |
| 2020 | 870.72 Thousand CAD | -45.97% |
| 2019 | 1.61 Million CAD | -44.77% |
| 2018 | 2.91 Million CAD | 28.76% |
| 2017 | 2.26 Million CAD | -14.1% |
| 2016 | 2.63 Million CAD | 52.45% |
| 2015 | 1.73 Million CAD | 124.39% |
| 2014 | 771.24 Thousand CAD | 301.78% |
| 2013 | 191.95 Thousand CAD | -59.11% |
| 2012 | 469.48 Thousand CAD | -75.53% |
| 2011 | 1.91 Million CAD | -55.04% |
| 2010 | 4.26 Million CAD | 224.6% |
| 2009 | 1.31 Million CAD | -35.22% |
| 2008 | 2.02 Million CAD | 211.08% |
| 2007 | 652.41 Thousand CAD | 30.84% |
| 2006 | 498.61 Thousand CAD | -22.36% |
| 2005 | 642.22 Thousand CAD | 19.69% |
| 2004 | 536.58 Thousand CAD | 821.41% |
| 2003 | 58.23 Thousand CAD | -20.27% |
| 2002 | 73.03 Thousand CAD | 481.92% |
| 2001 | 12.55 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.00 CAD | -6.37% |
| 2024 Q1 | 319.32 Thousand CAD | -26.69% |
| 2023 Q2 | 511.85 Thousand CAD | 57.69% |
| 2023 Q4 | 435.58 Thousand CAD | -19.98% |
| 2023 Q3 | 544.34 Thousand CAD | 6.35% |
| 2023 FY | 1.89 Million CAD | 49.13% |
| 2023 Q1 | 324.6 Thousand CAD | -20.25% |
| 2022 FY | 1.26 Million CAD | -28.26% |
| 2022 Q1 | 199.72 Thousand CAD | -31.78% |
| 2022 Q2 | 265.34 Thousand CAD | 32.86% |
| 2022 Q3 | 397.21 Thousand CAD | 49.7% |
| 2022 Q4 | 407.03 Thousand CAD | 2.47% |
| 2021 Q2 | 341.85 Thousand CAD | -49.5% |
| 2021 FY | 1.76 Million CAD | 103.2% |
| 2021 Q3 | 457.72 Thousand CAD | 33.89% |
| 2021 Q4 | 292.75 Thousand CAD | -36.04% |
| 2021 Q1 | 676.97 Thousand CAD | 113.31% |
| 2020 FY | 870.72 Thousand CAD | -45.97% |
| 2020 Q4 | 317.35 Thousand CAD | 88.06% |
| 2020 Q3 | 168.75 Thousand CAD | -2.75% |
| 2020 Q2 | 173.51 Thousand CAD | -17.9% |
| 2020 Q1 | 211.33 Thousand CAD | 10.74% |
| 2019 FY | 1.61 Million CAD | -44.77% |
| 2019 Q3 | 406.98 Thousand CAD | -2.5% |
| 2019 Q2 | 417.41 Thousand CAD | -30.16% |
| 2019 Q1 | 597.64 Thousand CAD | -0.07% |
| 2019 Q4 | 190.83 Thousand CAD | -53.11% |
| 2018 FY | 2.91 Million CAD | 28.76% |
| 2018 Q4 | 598.06 Thousand CAD | -16.78% |
| 2018 Q3 | 718.61 Thousand CAD | -14.2% |
| 2018 Q2 | 837.54 Thousand CAD | 9.65% |
| 2018 Q1 | 763.86 Thousand CAD | 1.83% |
| 2017 Q3 | 629.03 Thousand CAD | 47.91% |
| 2017 FY | 2.26 Million CAD | -14.1% |
| 2017 Q1 | 461.89 Thousand CAD | -40.89% |
| 2017 Q2 | 425.27 Thousand CAD | -7.93% |
| 2017 Q4 | 750.1 Thousand CAD | 19.25% |
| 2016 Q1 | 914.26 Thousand CAD | 35.08% |
| 2016 FY | 2.63 Million CAD | 52.45% |
| 2016 Q2 | 449.64 Thousand CAD | -50.82% |
| 2016 Q4 | 781.4 Thousand CAD | 58.54% |
| 2016 Q3 | 492.88 Thousand CAD | 9.62% |
| 2015 FY | 1.73 Million CAD | 124.39% |
| 2015 Q4 | 676.8 Thousand CAD | 9.58% |
| 2015 Q1 | 460.75 Thousand CAD | 12.44% |
| 2015 Q2 | 700.66 Thousand CAD | 52.07% |
| 2015 Q3 | 617.64 Thousand CAD | -11.85% |
| 2014 Q3 | 157.3 Thousand CAD | -38.94% |
| 2014 Q2 | 257.61 Thousand CAD | 10.33% |
| 2014 Q1 | 233.49 Thousand CAD | 112.97% |
| 2014 FY | 771.24 Thousand CAD | 301.78% |
| 2014 Q4 | 409.78 Thousand CAD | 160.51% |
| 2013 Q3 | 169.03 Thousand CAD | 71.1% |
| 2013 Q1 | 34.88 Thousand CAD | 8.26% |
| 2013 Q2 | 98.79 Thousand CAD | 183.21% |
| 2013 Q4 | 109.63 Thousand CAD | -35.14% |
| 2013 FY | 191.95 Thousand CAD | -59.11% |
| 2012 FY | 469.48 Thousand CAD | -75.53% |
| 2012 Q2 | 148.56 Thousand CAD | 174.74% |
| 2012 Q3 | 26.06 Thousand CAD | -82.46% |
| 2012 Q4 | 32.22 Thousand CAD | 23.63% |
| 2012 Q1 | 54.07 Thousand CAD | -24.89% |
| 2011 Q1 | 272.66 Thousand CAD | -79.14% |
| 2011 FY | 1.91 Million CAD | -55.04% |
| 2011 Q3 | 194.85 Thousand CAD | -79.81% |
| 2011 Q4 | 71.99 Thousand CAD | -63.05% |
| 2011 Q2 | 965.02 Thousand CAD | 253.93% |
| 2010 Q2 | 1.12 Million CAD | -38.96% |
| 2010 Q3 | 348.28 Thousand CAD | -68.97% |
| 2010 Q1 | 1.83 Million CAD | 202.58% |
| 2010 Q4 | 1.3 Million CAD | 275.22% |
| 2010 FY | 4.26 Million CAD | 224.6% |
| 2009 Q1 | 255.04 Thousand CAD | -19.22% |
| 2009 Q2 | 459.64 Thousand CAD | 80.22% |
| 2009 Q3 | 699.23 Thousand CAD | 52.12% |
| 2009 Q4 | 607.61 Thousand CAD | -13.1% |
| 2009 FY | 1.31 Million CAD | -35.22% |
| 2008 FY | 2.02 Million CAD | 211.08% |
| 2008 Q4 | 315.7 Thousand CAD | 12.09% |
| 2008 Q3 | 281.65 Thousand CAD | -69.44% |
| 2008 Q2 | 921.57 Thousand CAD | 159.05% |
| 2008 Q1 | 355.75 Thousand CAD | -40.34% |
| 2007 Q3 | 155.93 Thousand CAD | -45.63% |
| 2007 Q2 | 286.78 Thousand CAD | 146.64% |
| 2007 Q1 | 116.27 Thousand CAD | 1.89% |
| 2007 Q4 | 596.29 Thousand CAD | 282.4% |
| 2007 FY | 652.41 Thousand CAD | 30.84% |
| 2006 Q4 | 114.12 Thousand CAD | -15.61% |
| 2006 Q1 | 134.47 Thousand CAD | -15.73% |
| 2006 Q2 | 89.57 Thousand CAD | -33.39% |
| 2006 Q3 | 135.22 Thousand CAD | 50.97% |
| 2006 FY | 498.61 Thousand CAD | -22.36% |
| 2005 Q1 | 159.25 Thousand CAD | -0.47% |
| 2005 Q2 | 160.17 Thousand CAD | 0.58% |
| 2005 Q3 | 114.98 Thousand CAD | -28.21% |
| 2005 Q4 | 159.57 Thousand CAD | 38.78% |
| 2005 FY | 642.22 Thousand CAD | 19.69% |
| 2004 FY | 536.58 Thousand CAD | 821.41% |
| 2004 Q4 | 160.01 Thousand CAD | -3.52% |
| 2004 Q3 | 165.84 Thousand CAD | -8.25% |
| 2004 Q2 | 180.74 Thousand CAD | -20.17% |
| 2004 Q1 | 226.4 Thousand CAD | 99.28% |
| 2003 Q1 | 11.73 Thousand CAD | -29.89% |
| 2003 Q4 | 113.6 Thousand CAD | 975.32% |
| 2003 Q3 | 10.56 Thousand CAD | -51.99% |
| 2003 FY | 58.23 Thousand CAD | -20.27% |
| 2003 Q2 | 22 Thousand CAD | 87.57% |
| 2002 Q4 | 16.73 Thousand CAD | 115.42% |
| 2002 FY | 73.03 Thousand CAD | 481.92% |
| 2002 Q3 | 7767.00 CAD | 0.0% |
| 2001 FY | 12.55 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -14.718% |
| Arrayit Corporation | 6.19 Million USD | 80.583% |
| Atlantic International Corp. | 5.57 Million USD | 78.427% |
| Biocept, Inc. | 29.4 Million USD | 95.907% |
| Bioqual, Inc. | 7.44 Million USD | 83.844% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -55.852% |
| DermTech, Inc. | 104.01 Million USD | 98.843% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.277% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 94.681% |
| iMD Companies, Inc. | 151.8 Thousand USD | -692.704% |
| IDenta Corp. | 662.97 Thousand USD | -81.515% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 94.052% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -2995.075% |
| InVitro International | 661.32 Thousand USD | -81.968% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 83.046% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -1970.822% |
| Medical Imaging Corp. | 1.91 Million USD | 37.066% |
| NovelStem International Corp. | 3.53 Million USD | 65.985% |
| Optigenex Inc. | 1.28 Million USD | 6.559% |
| PharmChem, Inc. | 2.93 Million USD | 58.946% |
| Proteome Sciences plc | 3.26 Million USD | 63.176% |
| Response Genetics, Inc | 25.31 Million USD | 95.247% |
| Rennova Health, Inc. | 7.67 Million USD | 84.326% |
| RushNet, Inc. | 1.78 Million USD | 32.746% |
| ScreenPro Security Inc. | 3.23 Million USD | 62.846% |
| Stella Diagnostics Inc. | 11.42 Million USD | 89.469% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 83.612% |
| Todos Medical Ltd. | 14.05 Million USD | 91.44% |